Joel R. Eisner

2.0k total citations · 1 hit paper
42 papers, 1.5k citations indexed

About

Joel R. Eisner is a scholar working on Pulmonary and Respiratory Medicine, Genetics and Cancer Research. According to data from OpenAlex, Joel R. Eisner has authored 42 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 12 papers in Genetics and 12 papers in Cancer Research. Recurrent topics in Joel R. Eisner's work include Prostate Cancer Treatment and Research (22 papers), Estrogen and related hormone effects (11 papers) and Hormonal and reproductive studies (9 papers). Joel R. Eisner is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Estrogen and related hormone effects (11 papers) and Hormonal and reproductive studies (9 papers). Joel R. Eisner collaborates with scholars based in United States, United Kingdom and Switzerland. Joel R. Eisner's co-authors include David H. Abbott, Daniel A. Dumesic, Joseph W. Kemnitz, Ricki J. Colman, Edwina Baskin-Bey, Robert W. Goy, Anthony Elias, Ayca Gucalp, Tiffany A. Traina and Melissa A. Barnett and has published in prestigious journals such as Journal of Clinical Investigation, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Joel R. Eisner

41 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Male breast cancer: a disease distinct from female breast cancer

2018 230 citations Ayca Gucalp, Tiffany A. Traina et al. Breast Cancer Research and Treatment profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joel R. Eisner United States	17	608	576	353	294	258	42	1.5k
Dorothea Fischer Germany	18	241 0.4×	217 0.4×	275 0.8×	149 0.5×	130 0.5×	71	1.2k
Christian De Geyter Switzerland	23	1.1k 1.8×	853 1.5×	409 1.2×	201 0.7×	35 0.1×	92	1.9k
John E. Nichols United States	17	365 0.6×	208 0.4×	214 0.6×	264 0.9×	29 0.1×	36	1.0k
Isabelle Berthaut France	21	771 1.3×	464 0.8×	481 1.4×	263 0.9×	58 0.2×	47	1.3k
Norio Takamoto Japan	16	165 0.3×	104 0.2×	400 1.1×	262 0.9×	112 0.4×	24	1.1k
Ilma Simoni Brum Brazil	20	207 0.3×	125 0.2×	319 0.9×	111 0.4×	99 0.4×	67	843
B. Hinney Germany	22	439 0.7×	261 0.5×	284 0.8×	349 1.2×	23 0.1×	60	1.2k
Glen E. Hofmann United States	28	1.6k 2.7×	1.3k 2.3×	281 0.8×	219 0.7×	68 0.3×	63	2.5k
Viktoria von Schönfeldt Germany	19	507 0.8×	475 0.8×	300 0.8×	206 0.7×	31 0.1×	49	1.1k
Satoshi Ichigo Japan	25	563 0.9×	131 0.2×	637 1.8×	527 1.8×	53 0.2×	89	1.4k

Countries citing papers authored by Joel R. Eisner

Since Specialization

Citations

This map shows the geographic impact of Joel R. Eisner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel R. Eisner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel R. Eisner more than expected).

Fields of papers citing papers by Joel R. Eisner

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel R. Eisner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel R. Eisner. The network helps show where Joel R. Eisner may publish in the future.

Co-authorship network of co-authors of Joel R. Eisner

This figure shows the co-authorship network connecting the top 25 collaborators of Joel R. Eisner. A scholar is included among the top collaborators of Joel R. Eisner based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel R. Eisner. Joel R. Eisner is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Eisner, Joel R., Yuelong Guo, Yoichiro Shibata, et al.. (2024). The Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2–Based Immunotherapies. The Journal of Immunology. 213(1). 29–39. 2 indexed citations

Eisner, Joel R., Gregory M. Mayhew, James M. Davison, et al.. (2023). Association of Antifolate Response Signature Status and Clinical Activity of Pemetrexed-Platinum Chemotherapy in Non–Small Cell Lung Cancer: The Piedmont Study. Clinical Cancer Research. 29(16). 3203–3213.

Lopez, Juanita, Simon Haefliger, Ruth Plummer, et al.. (2023). Lisavanbulin in patients with recurrent glioblastoma: Phase 2a results and a consolidated analysis of response-predictive biomarkers.. Journal of Clinical Oncology. 41(16_suppl). 2044–2044. 1 indexed citations

Eisner, Joel R., Gregory M. Mayhew, Yoichiro Shibata, et al.. (2022). Distinct Predictive Immunogenomic Profiles of Response to Immune Checkpoint Inhibitors and IL2: A Real-world Evidence Study of Patients with Advanced Renal Cancer. Cancer Research Communications. 2(8). 894–903. 1 indexed citations

Michmerhuizen, Anna R., Rachel Schwartz, Kari Wilder-Romans, et al.. (2022). Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. British Journal of Cancer. 127(5). 927–936. 4 indexed citations

Christenson, Jessica L., Michelle M. Williams, Nicole S. Spoelstra, et al.. (2021). Activity of Combined Androgen Receptor Antagonism and Cell Cycle Inhibition in Androgen Receptor Positive Triple Negative Breast Cancer. Molecular Cancer Therapeutics. 20(6). 1062–1071. 28 indexed citations

Rose, Tracy L., William H. Weir, Gregory M. Mayhew, et al.. (2021). Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. British Journal of Cancer. 125(9). 1251–1260. 108 indexed citations

Madan, Ravi A., Keith T. Schmidt, Fatima Karzai, et al.. (2020). Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment. Clinical Genitourinary Cancer. 18(4). 258–267.e1. 14 indexed citations

Peer, Cody J., Keith T. Schmidt, Joel R. Eisner, et al.. (2019). A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer. Cancer Chemotherapy and Pharmacology. 84(4). 759–770. 3 indexed citations

10.

Gupta, Shilpa, Luke T. Nordquist, Mark T. Fleming, et al.. (2018). Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 24(21). 5225–5232. 14 indexed citations

11.

Bardia, Aditya, Ayca Gucalp, Nashat Gabrail, et al.. (2018). Phase 1 study of seviteronel, a selective CYP17 lyase and androgen receptor inhibitor, in women with estrogen receptor-positive or triple-negative breast cancer. Breast Cancer Research and Treatment. 171(1). 111–120. 35 indexed citations

12.

Gucalp, Ayca, Tiffany A. Traina, Joel R. Eisner, et al.. (2018). Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment. 173(1). 37–48. 230 indexed citations breakdown →

13.

Norris, John D., Stephanie J. Ellison, David B. Stagg, et al.. (2017). Androgen receptor antagonism drives cytochrome P450 17A1 inhibitor efficacy in prostate cancer. Journal of Clinical Investigation. 127(6). 2326–2338. 38 indexed citations

14.

Eisner, Joel R., et al.. (2014). Highly-selective 4-(1,2,3-triazole)-based P450c17a 17,20-lyase inhibitors. Bioorganic & Medicinal Chemistry Letters. 24(11). 2444–2447. 45 indexed citations

15.

Bruns, Cristin M., Scott T. Baum, Ricki J. Colman, et al.. (2004). Insulin Resistance and Impaired Insulin Secretion in Prenatally Androgenized Male Rhesus Monkeys. The Journal of Clinical Endocrinology & Metabolism. 89(12). 6218–6223. 73 indexed citations

16.

Eisner, Joel R., Daniel A. Dumesic, Joseph W. Kemnitz, Ricki J. Colman, & David H. Abbott. (2003). Increased Adiposity in Female Rhesus Monkeys Exposed to Androgen Excess During Early Gestation. Obesity Research. 11(2). 279–286. 114 indexed citations

17.

Eisner, Joel R., Melissa A. Barnett, Daniel A. Dumesic, & David H. Abbott. (2002). Ovarian hyperandrogenism in adult female rhesus monkeys exposed to prenatal androgen excess. Fertility and Sterility. 77(1). 167–172. 114 indexed citations

18.

Dumesic, Daniel A., Michael Festersen Nielsen, David H. Abbott, et al.. (1999). Insulin action during variable hyperglycemic–hyperinsulinemic infusions in hyperandrogenic anovulatory patients and healthy women. Fertility and Sterility. 72(3). 458–466. 6 indexed citations

19.

Dumesic, Daniel A., David H. Abbott, Joel R. Eisner, et al.. (1998). Pituitary desensitization to gonadotropin-releasing hormone increases abdominal adiposity in hyperandrogenic anovulatory women. Fertility and Sterility. 70(1). 94–101. 37 indexed citations

20.

Dumesic, Daniel A., David H. Abbott, Joel R. Eisner, & Robert W. Goy. (1997). Prenatal exposure of female rhesus monkeys to testosterone propionate increases serum luteinizing hormone levels in adulthood. Fertility and Sterility. 67(1). 155–163. 134 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact